Precision oral therapy selection for Type 2 Diabetes
Fields marked with * are mandatory.
The Glycemic Decision Engine (GDE) is an evidence-based clinical decision-support tool designed to assist healthcare professionals in selecting the most appropriate oral medications for patients with Type 2 Diabetes Mellitus (T2DM). It integrates patient-specific factors with current diabetes management guidelines to generate safe, personalized, and guideline-concordant treatment recommendations.
This tool helps clinicians streamline the complex process of choosing oral antidiabetic therapy by matching individual patient profiles with optimal drug classes and combinations. It supports rational prescribing, improves treatment consistency, and enhances glycemic outcomes.
The selector analyzes key clinical inputs such as:
HbA1c level and glycemic target
Duration of diabetes
Body mass index (BMI)
Renal function (eGFR)
Presence of cardiovascular disease (ASCVD)
Heart failure or CKD status
Risk of hypoglycemia
Weight considerations
Cost sensitivity and access
Using guideline-based algorithms (e.g., ADA/EASD aligned logic), the tool recommends the most suitable oral hypoglycemic agents and escalation pathways.
Personalized OHA selection based on patient phenotype
First-line and add-on therapy guidance
Renal dose safety checks
Hypoglycemia risk stratification
Weight impact considerations
Cardio-renal benefit prioritization
Contraindication alerts
Stepwise treatment escalation pathway
Quick clinical summary output
Endocrinologists
General physicians
Diabetologists
Nurse practitioners
Telemedicine platforms
Medical residents and students
Promotes evidence-based diabetes care
Reduces prescribing variability
Improves safety in renal and cardiac patients
Saves clinical decision time
Supports guideline adherence
Enhances individualized therapy selection
This tool is intended for educational and clinical decision-support purposes only. Final treatment decisions should always be based on clinician judgment and current local guidelines.